LIXTE Biotechnology Holdings, Inc. filings document a clinical-stage oncology issuer with common stock and warrants outstanding, material-event reporting and capital-structure changes. Recent Form 8-K disclosures cover material agreements for Liora Technologies Europe Ltd., executive compensation arrangements, Regulation FD updates and governance changes tied to board appointments, committee roles and preferred-stock designation rights.
The record also includes disclosures relevant to LB-100 development, the Liora proton therapy subsidiary, public warrants, preferred-stock rights, shareholder voting matters, forward-looking risk language and capital allocation. These filings formalize the company's operating, governance and security-structure information for its biotechnology and med-tech activities.
LIXTE Biotechnology Holdings, Inc. entered into an Allocation Deed and a Consultancy Agreement with its subsidiary Liora Technologies Europe Ltd. and consultant Sidney Braun. Braun becomes CEO and a director of Liora, with a GBP 50,000 signing bonus and a GBP 25,000 monthly retainer, both exclusive of VAT.
Under the Allocation Deed, Braun is entitled to 20% of the net purchase price if there is a sale of Liora or any Liora successor. LIXTE also issued a press release highlighting Braun’s healthcare background and Liora’s LiGHT System proton therapy technology for cancer treatment.
LIXTE Biotechnology Holdings, Inc. entered into an Allocation Deed and a Consultancy Agreement with its subsidiary Liora Technologies Europe Ltd. and consultant Sidney Braun. Braun becomes CEO and a director of Liora, with a GBP 50,000 signing bonus and a GBP 25,000 monthly retainer, both exclusive of VAT.
Under the Allocation Deed, Braun is entitled to 20% of the net purchase price if there is a sale of Liora or any Liora successor. LIXTE also issued a press release highlighting Braun’s healthcare background and Liora’s LiGHT System proton therapy technology for cancer treatment.
Lixte Biotechnology Holdings, Inc. filed a current report describing a recent treasury move into digital assets. On September 10, 2025, the company issued a press release announcing an initial purchase of digital currency totaling $2.6 million.
The disclosure is furnished under Regulation FD, meaning it is provided for informational purposes and is not treated as filed financial information under securities laws. The report also includes standard forward-looking statement cautions about risks and uncertainties that could cause actual results to differ from expectations.
Lixte Biotechnology Holdings, Inc. director Guy Primus filed an initial insider ownership report on Form 3 as of 09/01/2025. The filing states that no securities of the company are beneficially owned, and both the non-derivative and derivative securities tables are blank.
Peter Stazzone, appointed Chief Financial Officer of Lixte Biotechnology Holdings, Inc., was granted options to buy 50,000 shares of common stock at an exercise price of $4.45 per share. The options vest in four equal tranches: 25% on 09/01/2025, 25% on 12/15/2025, 25% on 03/15/2026, and 25% on 06/15/2026, subject to continuous service and possible acceleration on certain events. Each option covers one share and the options expire five years after the grant date, making the exercisable common shares underlying the grant 50,000.
Peter Stazzone filed a Form 3 reporting an initial statement of beneficial ownership for Lixte Biotechnology Holdings, Inc. (symbol shown as LIXT) related to an event on 09/01/2025. The filing identifies Mr. Stazzone as an officer with the title Chief Financial Officer and indicates the form was filed by one reporting person. The Form 3 states no securities are beneficially owned by the reporting person. The filing is signed and dated 09/04/2025.
Lixte Biotechnology Holdings, Inc. (LIXTW) Form 3 shows that Felix Lourdes, identified as a Director, filed an initial statement dated 09/01/2025 but reported no securities beneficially owned in the issuer. The signature block is dated 09/04/2025. The filing confirms the director relationship but discloses zero direct or indirect holdings in the company.
Jason David Sawyer, a newly appointed director of Lixte Biotechnology Holdings, Inc. (ticker: LIXT/LIXTW), was granted options to purchase 25,000 shares on 08/15/2025. The options have an exercise price of $3.59 per share, become exercisable immediately for 50% of the grant and vest the remaining 50% in increments—12.5% on 12/31/2025 and 12.5% on the last day of each subsequent calendar quarter—subject to continuous service, and expire on 08/15/2030. The grant was made in connection with Sawyer's appointment to the company’s board. The Form 4 was signed by the reporting person on 08/18/2025.
Michael Andrew Holloway was appointed to the board of Lixte Biotechnology Holdings, Inc. and on August 15, 2025 was granted options to purchase 25,000 shares of common stock at an exercise price of $3.59 per share. The options vest 50% immediately on the effective date and the remaining 50% vests in increments of 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested. The options are exercisable beginning August 15, 2025 and expire on August 15, 2030. The Form 4 was signed by Mr. Holloway on August 18, 2025.